Dr. Nida Hamiduzzaman, MD

Dr. Hamiduzzaman practices at Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD in Los Angeles, California.

Dr. Hamiduzzaman's NPI, 1720271604, was assigned on August 23, 2007. Dr. Hamiduzzaman graduated from American University of the Caribbean School of Medicine in 2006. Dr. Hamiduzzaman holds California license A110641.

Dr. Hamiduzzaman's primary practice is Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD, at 1450 San Pablo St, Los Angeles, CA 90033.

Dr. Hamiduzzaman's primary practice is Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD in Los Angeles, California. Dr. Hamiduzzaman is also affiliated with Keck Hospital of USC. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Hamiduzzaman to 1 more hospital, 2 home health agencies, 1 group practice or clinic and 1 other site, each named with a free account. Dr. Hamiduzzaman's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hamiduzzaman practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Hamiduzzaman's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Hamiduzzaman is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Hamiduzzaman's licenses on file in 3 states: California, Florida and Oklahoma.

Dmand AI lists cardiac arrhythmia, heart attack, syncope & collapse and urinary tract infection among the conditions Dr. Hamiduzzaman treats.

CMS data shows 189 Medicare services from Dr. Hamiduzzaman across 4 procedure codes in 2024, all of them office visits, for 143 Medicare patients. Medicare paid $12,568 for them.

CMS counts 143 Medicare patients who saw Dr. Hamiduzzaman in 2024. The largest group is 65 to 74, with 70 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 48% are also on Medicaid. Their average risk score is 1.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hamiduzzaman's median patient age at 64, with 61% women.

In 2024, Dr. Hamiduzzaman wrote 333 Medicare Part D claims for 100 patients. 88% of them were for generic drugs. CMS names the drug for 115 of them, across 7 drugs with 11 or more claims each, at $1,275 in total drug cost. In 2020, CMS named 28 claims across 2 drugs.

Dr. Hamiduzzaman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hamiduzzaman as offering telehealth.

Dr. Hamiduzzaman graduated from American University of the Caribbean School of Medicine in 2006.

Dr. Hamiduzzaman is in network with 6 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.